Fundraising FoxCambridge Innovation Capital — 2024 Investments
7 investments dated 2024 · listed companies and verified rows first · show all
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge, GB
Gregory Winter(Director)inNIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)MICHAEL SKYNNER(Executive Officer)in
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCDementia Discovery FundLongwood FundRidgeback CapitalSR One Capital Management+4 more
52North Health develops NeutroCheck, a diagnostic tool that identifies neutropenia in chemotherapy patients presenting with fever, enabling risk stratification and reducing unnecessary emergency department visits.
BiotechDigital HealthHealthtechMedical DevicesCambridge, GB
Co-investorsMeridian Health VenturesCambridge Angels groupFuture Planet CapitalParkwalk AdvisorsSie VenturesCrista Galli Ventures+2 more
Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured.
BiotechDeep TechNew MaterialsCambridge, GB
Jason Chin(Professor)Jason W. Chin(Founder)Julius Fredens(Founder)Ola Wlodek, PhD(CEO)Prof. Jason Chin, PhD(CSO & Founder)
Co-investors+ND CapitalAmadeus Capital PartnersFine Structures VenturesGENERAL INCEPTIONLongeVCOMX Ventures+2 more
Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.
AI & Machine LearningBiotechHealthtechMontreal, CA
Claude PerreaultPierre Thibault
Co-investorsAdvent Life SciencesCTI Life Sciences Fund L.P.adMare BioInnovationsFonds de solidarité FTQ
Exciting Instruments builds the EI-FLEX benchtop platform, a single-molecule fluorescence instrument combining smFRET, FCS and FCCS to measure biomolecular interactions and dynamics directly in solution.
BiotechDeep TechHardware
Timothy Craggs(Founder and CEO)
Co-investorsNorthern GritstoneEmpirical VenturesPraetura Ventures
Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis.
AI & Machine LearningBiotechLongevityCambridge, GB
Daniel Ives(Founder & CEO)inBrendan Swain(Co-founder & CSO)in
Co-investorsF-Prime CapitalIKJ CapitalKindred Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Clock Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.